Celcuity's breast cancer combo hits goals, teeing up FDA filing

Celcuity's Phase 3 VIKTORIA-1 trial for its gedatolisib combination in HR-positive, HER2-negative advanced breast cancer successfully met primary endpoints, with the triplet regimen reducing the risk of disease progression or death by 76% (HR 0.24) and the doublet by 67% (HR 0.33) compared to fulvestrant monotherapy. Progression-free survival was notably extended, quadrupling the likelihood of survival without disease progression relative to control. These "potentially practice-changing" results, coupled with favorable safety profiles, position Celcuity for an FDA approval filing in Q4.

Analysis

Celcuity Inc. has reported highly compelling Phase 3 data for its PI3K/mTOR inhibitor, gedatolisib, in HR-positive, HER2-negative advanced breast cancer. The VIKTORIA-1 trial met its primary endpoints, with the triplet regimen reducing the risk of disease progression or death by 76% (Hazard Ratio of 0.24) and the doublet regimen by 67% (HR of 0.33) compared to fulvestrant monotherapy. These hazard ratios significantly surpass the company's stated threshold for compelling results (HR < 0.5) and compare favorably to competitor drug data from Eli Lilly and Menarini. The extension in progression-free survival is substantial, increasing from 2.0 months in the control arm to 9.3 months for the triplet and 7.4 months for the doublet, a result described by an external expert as "potentially practice-changing." Furthermore, the drug demonstrated a favorable safety profile, with lower discontinuation rates due to adverse events than currently approved combinations. These positive results pave the way for a planned FDA submission in the fourth quarter of 2024, marking a significant de-risking event for the company and its lead asset.

Key Decisions for Investors

• The exceptionally strong efficacy and safety data from the Phase 3 trial substantially de-risks gedatolisib, suggesting investors should view this as a primary value-driving catalyst for Celcuity (CELC) leading up to its planned Q4 FDA filing.
• Monitor the competitive landscape, particularly how these practice-changing results position gedatolisib against therapies from AstraZeneca, Pfizer, and Eli Lilly, as physician adoption and market positioning will be critical for long-term value.
• Investors should look ahead to the detailed data presentation at an upcoming medical conference for further clinical validation and anticipate top-line data from the PIK3CA mutated cohort in 2025, which could further expand the drug's market potential.